Conference Track

Hepatitis Coinfection and Opportunistic Infections

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

48 Weeks Peginterferon alfa-2a/Ribavirin Treatment Superior to 24 Weeks for HIV/HCV Genotype 2 or 3 Coinfection
Risk of Liver-Related Death Decreases With Increasing Duration of Lamivudine-Based HAART in HIV/HBV-Coinfected Patients
First-line Tenofovir Plus Lamivudine Appears to Provide Similar Antiviral Potency as Sequential Use of Lamivudine Followed by Tenofovir in HIV/HBV-Coinfected Patients
Response to Treatment of Acute HCV Infection With Pegylated Interferon Alfa-2b Plus Ribavirin in Patients With HCV/HIV Coinfection
Hepatocellular Carcinoma Develops More Rapidly in Patients With HIV/HCV Coinfection
Treatment With Peginterferon Alfa-2a Plus Ribavirin Associated With Histologic Improvement Regardless of Virologic Response
High Prevalence of Exposure to Hepatitis C in Cohort of HIV-Positive Patients Initiating Antiretroviral Therapy
Increased Risk of HAART-Associated Hepatotoxicity Associated with Extent of Histologic Liver Damage Caused by Hepatitis C
Four- and Three-Drug TB Induction Regimens Demonstrate Similar Efficacy in TB/HIV Coinfected Patients in Setting of Low-Level Resistance to TB Agents
No Observed Increase in Complications in South African Patients Initiating Nevirapine-Based HAART With Concomitant Rifampin
Very Early Declines in HCV Viral Load Predict Treatment Response in HIV/HCV-Coinfected Patients

Expert Analysis

Hepatitis Coinfection and Opportunistic Infections

Program Director: John P. Phair, MD

Faculty:

Richard E. Chaisson, MD
Bruce Polsky, MD
Jürgen K. Rockstroh, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss parameters for treatment success in patients coinfected with HIV and hepatitis B or C.
Recount parameters for treatment selection in patients with HIV/TB coinfection.
Describe sequelae of HIV/HCV coinfection such as development of hepatocellular carcinoma and fibrotic histologic changes.
List factors related to hepatotoxicity in HIV/HCV and HIV/TB coinfection.

CME CREDIT INFORMATION

Release Date: 09/30/05

Expiration Date: 09/29/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.8 Nursing CE credits

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.